NCT00950924

Brief Summary

Axial hyperopia results when the length of the eye is too short for the eye to properly focus distance objects on the retina while the focusing system is relaxed. Emmetropization is the process by which the eye actively adjusts various components of the eye to gradually improve the focus of the eye. Emmetropization frequently involves either an increase or a decrease in the growth of the eye, particularly during infancy and childhood. Numerous animal studies suggest that if an animal is exposed to retinal images located behind the retina either centrally or peripherally, the eye will grow in the direction of the focused image. If an abnormally short eye has resulted in hyperopia, exposing such an eye to retinal images partially located behind the retina might encourage axial elongation, thus reducing the hyperopia.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jan 2015

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 30, 2009

Completed
4 days until next milestone

First Posted

Study publicly available on registry

August 3, 2009

Completed
5.4 years until next milestone

Study Start

First participant enrolled

January 1, 2015

Completed
6.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2021

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2022

Completed
Last Updated

January 12, 2021

Status Verified

January 1, 2021

Enrollment Period

6.8 years

First QC Date

July 30, 2009

Last Update Submit

January 11, 2021

Conditions

Keywords

HyperopiaRefractive ErrorOcular BiometricsAxial LengthContact LensesBifocal Contact Lenses

Outcome Measures

Primary Outcomes (1)

  • Axial length

    One year

Secondary Outcomes (1)

  • Refractive Error

    One year

Study Arms (2)

Bifocal Contact Lenses

EXPERIMENTAL

Simultaneous Vision Bifocal Soft Contact Lenses will be prescribed such that the distance vision as measured by manifest subjective refraction will be properly corrected by the near vision add power and undercorrected by the distance power.

Device: Simultaneous Vision Bifocal Soft Contact Lenses

Single Vision Soft Contact Lenses

PLACEBO COMPARATOR

Subjects will be fitted with single vision soft contact lenses with goal of corrected emmetropia at a distance of 20 feet.

Device: Single Vision Soft Contact Lenses

Interventions

Simultaneous Vision Bifocal Soft Contact Lenses will be prescribed such that the distance vision as measured by manifest subjective refraction will be properly corrected by the near vision add power and undercorrected by the distance power.

Bifocal Contact Lenses

Single vision soft contact lenses will be prescribed to properly correct the distance vision as measured by manifest subjective refraction.

Single Vision Soft Contact Lenses

Eligibility Criteria

Age5 Years - 12 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Aged 5-12
  • Hyperopia \> +1.25 each eye (cycloplegic refraction)
  • Ability to wear soft contact lenses

You may not qualify if:

  • Amblyopia
  • Strabismus
  • Astigmatism \> 1.00 diopters
  • Axial Length \> 24.00 mm

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

711 Kains Ave

San Bruno, California, 94066, United States

Location

MeSH Terms

Conditions

HyperopiaRefractive Errors

Condition Hierarchy (Ancestors)

Eye Diseases

Study Officials

  • Thomas A Aller, O.D.

    Unafilliated

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 30, 2009

First Posted

August 3, 2009

Study Start

January 1, 2015

Primary Completion

October 1, 2021

Study Completion

January 1, 2022

Last Updated

January 12, 2021

Record last verified: 2021-01

Locations